GlassScriptPhysician profile
Nehal Mohammed Aleemuddin
NPI 1518321082
$11,968.35
in general payments reported to CMS, 2019-2025
51 companies · $3,143 in 2025
The $3,143 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $587 · 2021: $1,312 · 2022: $1,851 · 2023: $2,105 · 2024: $2,779 · 2025: $3,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,026.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,843.77 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Novo Nordisk INC | $1,581.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,187.80 | 2020-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,051.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $917.33 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $780.03 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $770.58 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Glaxosmithkline, LLC. | $618.22 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $442.48 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $338.47 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.77 | 2020-2025 | Xifaxan |
| Exact Sciences Corporation | $216.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $162.69 | 2021-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $152.82 | 2019-2022 | |
| Esperion Therapeutics, INC. | $142.56 | 2021-2025 | Nexletol |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Aleemuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.